Clinical trials: SARS-CoV 2
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
SARS-CoV 2
Efficacy of Tocilizumab on Patients With COVID-19
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
- Trial name
- NCT04356937
- Testing
- Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 243 people
- Sponsor
- Massachusetts General Hospital
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
COVID-19, SARS-CoV 2
COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as…
- Trial name
- PIIPPI (NCT04364802)
- Testing
- Povidone-Iodine Nasal Spray and Gargle
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Nikita Gupta
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Covid19, SARS-CoV Infection
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
- Trial name
- COVID-FIS (NCT04537299)
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT05629962
- Testing
- Bemnifosbuvir (BEM)
- Where
- 263 sites in United States, Argentina and 17 more
- Volunteers
- 2,285 people
- Sponsor
- Atea Pharmaceuticals, Inc.
SARS-CoV 2, COVID-19
Convalescent Plasma for Early Treatment of COVID-19
This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as early treatment.
- Trial name
- NCT04390503
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%)
- Where
- Brazil
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Andrew Eisenberger
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04399980
- Testing
- Mavrilimumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, SARS-CoV 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest…
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease
- Trial name
- AMPoL (NCT04409873)
- Testing
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Francisco
SARS-CoV-2 Acute Respiratory Disease, Covid19
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality.
- Trial name
- STC-19 (NCT04371471)
- Testing
- STC-19 score
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
COVID-19 Disease
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An open label phase 2 trial to evaluate safety, tolerability and immunogenicity of the ABNCoV2 vaccine after intramuscular (IM) application.
- Trial name
- NCT05077267
- Testing
- ABNCoV2 100ug, ABNCoV2 50ug
- Where
- 2 sites in Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04492514
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kristin Hudock